GM-CSF Antikörper

Antigen: GM-CSF

Synonyme: GMCSF, GM-CSF

Klonalität: Monoklonal (MP1-22E9)

Wirt: Ratte

Reaktivität: Maus

Applikation: ELISA (Fangantikörper), ELISPOT (Fangantikörper), Neutralisierung (Neut), Intrazelluläre Durchflusszytometrie (ICFC), Immunhistochemie (IHC)

Produktnummer: ABIN160408

Produktbeschreibung

Immunogen: Yeast-expressed, recombinant mouse GM-CSF.

Format: Low endotoxin (sterile), Low-endotoxin, azide-free (LEAF)

Isotyp: IgG2a, kappa chain  (Passende Sekundärantikörper)

Klon: MP1-22E9

Beschreibung: Growth/development granulocyte/macrophage progenitors, differentiates myeloblasts/monoblasts, synergizes with Epo proliferation of erythroid/megakaryocytic progenitors T cells, monocytes/macrophages, fibroblasts, endothelial cells, mast cells GM-CSF is a hematopoietic factor that is produced by T cells, macrophages, fibroblasts and endothelial cells. This multifunctional cytokine stimulates progenitor cells of neutrophils, eosinophils and macrophages. GM-CSF is also a differentiation and activating factor for granulocytic and monocytic cells. The MP1-22E9 antibody reacts with mouse granulocyte/macrophage-colony stimulating factor (GM-CSF). The MP1-22E9 antibody can neutralize the bioactivity of natural or recombinant GM-CSF. Synonyms: Granulocyte/macrophage-colony stimulating factor, CSF-alpha, Pluripoietin-alpha, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA) Regulation: Synergistic with IL-1, IL-3, G-CSF, E21R competitive antagonist for receptor binding, stored in ECM with heparan sulfate proteoglycans Structure: Cytokine, 22 kD (Mammalian)

Anwendungen

Applikationshinweise: ELISA or ELISPOT Capture: The purified MP1-22E9 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MP1-31G6 antibody (ABIN160410) as the detecting antibody. The LEAF(TM) purified antibody is suggested for ELISPOT capture. Flow Cytometry: The fluorochrome-labeled MP1-22E9 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify GM-CSF -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.com and click on the support section. Neutralization: The LEAF(TM) purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm sterile-filtered) is recommended for neutralization of mouse GM-CSF bioactivity in vivo and in vitro (ABIN160408). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry. Each lot of this antibody is quality control tested by ELISA assay. For ELISA or ELISPOT Capture, the antibody should be titrated between 1-4 µg/ml to determine optimal concentration. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Reinheit: LEAF

Reinigung: The antibody was purified by affinity chromatography.

Buffer: Phosphate-buffered solution, pH 7.2, containing no preservative. 0.2 µm filter sterilized. Endotoxin level is < 0.1 EU/µg of the protein (< 0.01 ng/µg of the protein) as determined by the LAL test.

Lagerung: The antibody solution should be stored undiluted at 4 °C. This LEAF(TM) solution contains no preservative, handle under aseptic conditions.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

anti-GM-CSF antibody

Publikationen

Publikationen: Abrams, Roncarolo, Yssel et al.: "Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples." in: Immunological reviews, Vol. 127, pp. Mai 24, 1992 (PubMed).

Negrin, Greenberg: "Therapy of hematopoietic disorders with recombinant colony-stimulating factors." in: Advances in pharmacology (San Diego, Calif.), Vol. 23, pp. 263-96, 1992 (PubMed).

Demetri, Griffin: "Granulocyte colony-stimulating factor and its receptor." in: Blood, Vol. 78, Issue 11, pp. 2791-808, 1991 (PubMed).

Fan, OBrian, Ioannides et al.: "Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer." in: In vivo (Athens, Greece), Vol. 5, Issue 6, pp. 571-7, 1992 (PubMed).

Sander, Andersson, Andersson: "Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure." in: Immunological reviews, Vol. 119, pp. 65-93, 1991 (PubMed).

Nozaki, Abrams, Pearce et al.: "Augmentation of granulocyte/macrophage colony-stimulating factor expression by ultraviolet irradiation is mediated by interleukin 1 in Pam 212 keratinocytes." in: The Journal of investigative dermatology, Vol. 97, Issue 1, pp. 10-4, 1991 (PubMed).

Suda, OGarra, MacNeil et al.: "Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas." in: Cellular immunology, Vol. 129, Issue 1, pp. 228-40, 1990 (PubMed).

Sander, Hoeiduen, Andersson et al.: "Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining." in: Journal of immunological methods, Vol. 166, Issue 2, pp. 201-14, 1994 (PubMed).

Larkin, Renukaradhya, Sriram et al.: "CD44 differentially activates mouse NK T cells and conventional T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 177, Issue 1, pp. 268-79, 2006 (PubMed).